Psychiatric co-morbidity among subjects with heroin and cocaine use disorders and its association with HCV infection

References

• Amodio, P., Salari, L., Montagnese, S., Schiff, S., Neri, D., Bianco, T., & Minazzato, L. (2012). Hepatitis C virus infection and health-related quality of life. World Journal of Gastroenterology, 18, 2295–2299
   PubMedGoogle Scholar
• Butt, A. A., Evans, R., Skanderson, M., & Shakil, A. O. (2006). Comorbid medical and psychiatric conditions and substance abuse in HCV infected persons on dialysis. Journal of Hepatology, 44, 864–868
   PubMed Web of Science ®Google Scholar
• Butt, A. A., Khan, U. A., McGinnis, K. A., Skanderson, M., & Kent Kwoh, C. (2007). Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. Journal of Viral Hepatitis, 14, 890–896
   PubMed Web of Science ®Google Scholar
• Carmen, E., & Brady, S.M. (1990). AIDS risk and prevention for the chronic mentally ill. Hospital and Community Psychiatry, 41, 652–657
   PubMedGoogle Scholar
• Compton, W. M., Conway, K. P., Stinson, F. S., Colliver, J. D., & Grant, B. F. (2005). Prevalence, correlates, and comorbidity of DSM-IV antisocial personality syndromes and alcohol and specific drug use disorders in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry, 66, 667–685
   Google Scholar
• Conway, K. P., Compton, W., Stinson, F. S., & Grant, B.F. (2006). Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry, 67, 247–257
   PubMed Web of Science ®Google Scholar
• Coverdale, J. H., & Turbott, S. H. (2000). Risk behaviors for sexually transmitted infections among men with mental disorder. Psychiatric Services, 51, 234–238
   PubMed Web of Science ®Google Scholar
• Dausey, D. J., & Desai, R. A. (2003). Psychiatric co-morbidity and the prevalence of HIV infection in a sample of patients in treatment for substance abuse. Journal of Nervous and Mental Disease, 191, 10–17
   PubMed Web of Science ®Google Scholar
• Des Jarlais, D. C., Perlis, T., Arasteh, K., Torian, L. V., Hagan, H., Beatrice, S., Smith, L., Wethers, J., Millike, J., Mildvan, D., Yancovitz, S., & Friedman, S. R. (2005). Reduction in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990–2001. AIDS, 19, 20–25
   PubMed Web of Science ®Google Scholar
• Dominitz, J. A., Boyko, E. J., Koepsell, T. D., Heagerty, P. J., Maynard, C., Sporleder, J. L., Stenhouse, A., Kling, M. A., Hrushesky, W., Zeilman, C., Sontag, S., Shah, N., Ona, F., Anand, B., Subik, M., Imperiale, T. F., Nakhle, S., Ho, S. B., Bini, E. J., Lockhart, B., Ahmad, J., Sasaki, A., van der Linden, B., Toro, D., Martinez-Souss, J., Huilgol, V., Eisen, S., & Young, K. A. (2005). Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology, 41, 88–89
   PubMedGoogle Scholar
• Fireman, M., Indest, D. W., Blackwell, A., Whitehead, A. J., & Hauser, P. (2005). Addressing tri-morbidity (hepatitis C psychiatric and substance use disorders): The importance of routine mental health screening as a component of a co-management model of care. Clinical Infectious Diseases, 40, 286–291
   PubMed Web of Science ®Google Scholar
• Fried, M. W., Shiffman, M. L., & Reddy, K. R. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 347, 975–982
   PubMed Web of Science ®Google Scholar
• Glantz, M. D., Anthony, J. C., Berglund, P. A., Degenhardt, L., Dierker, L., Kalaydjian, A., Merikangas, K. R., Ruscio, A. M., Swendsen, J., & Kessler, R. C. (2009). Mental disorders as risk factors for later substance dependence: Estimates of optimal prevention and treatment benefits. Psychology Medicine, 39, 1365–1377
   PubMed Web of Science ®Google Scholar
• Grassi, L., Biancosino, B., Righi, R., Finotti, L., & Person, L. (2001). Knowledge about HIV Transmission and prevention among Italian patients with psychiatric disorders. Psychiatric Service, 52, 679–681
   PubMedGoogle Scholar
• Hadziyannis, S. J., Sette, H. J., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H. J., Bernstein, D., Rizzetto, M., Zeuzem, S., Pockros, P. J., Lin, A., & Ackrill, A. M. (2004). Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine, 140, 346–455
   PubMed Web of Science ®Google Scholar
• Hagan, H., Thiede, H., Des Jarlais, & D. C. (2004). Hepatitis C virus infection among injection drug users: Survival analysis of time to seroconversion. Epidemiology, 15, 543–549
   PubMed Web of Science ®Google Scholar
• Hasin, D. S., Stinson, F. S., OgburnE, & Grant, B. F. (2007). Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry, 64, 830–842
   PubMed Web of Science ®Google Scholar
• Hellard, M. E., Nguyen, O. K., Guy, R. J., Jardine, D., Mijcn, A., & Higgs, P. (2006). The prevalence and risk behaviours associated with the transmission of blood-borne viruses among ethnic-Vietnamese injecting drug users. Australian and New Zealand Journal of Public Health, 30, 519–525
   PubMed Web of Science ®Google Scholar
• Hercus, M., Lunman, D. I., & Hellard, M. (2005). Blood-borne viral and sexually transmissible infections among psychiatric populations: What are we doing about them? Australian and New Zealand Journal of Psychiatry, 391, 849–855
   Google Scholar
• Kershenobich, D. (2006). Indications and contraindications for treatment of Hepatitis C virus infection. Annals of Hepatology, 5, 22–23
   Google Scholar
• Lacey, C., Ellen, S., Devlin, H., Wright, E., & Mijch, A. (2007). Hepatitis C in psychiatry inpatients: Testing rates, prevalence and risk behaviours. Australian Psychiatry, 15, 315–319
   PubMed Web of Science ®Google Scholar
• Little, K., Hawkins, M. T., Sanson, A., Toumbourou, J. W., Smart, D., Vassallo, S., & O’Connor, M. (2012). The longitudinal prediction of alcohol consumption-related harms among young adults. Substance Use Misuse, 47, 1303–1317
   PubMed Web of Science ®Google Scholar
• Marsden, J., Eastwood, B., Bradbury, C., Dale-Perera, A., Farrell, M., Hammond, P., Knight, J., Randhawa, K., & Wright, C. (2009). Effectiveness of community treatments for heroin and crack cocaine addiction in England: A prospective, in-treatment cohort study. The Lancet, 374, 1262–1270
   PubMed Web of Science ®Google Scholar
• Marsden, J., Farrell, M., Bradbury, C., Dale-Perera, A., Eastwood, B., Roxburgh, M., & Taylor, S. (2008). Development of the treatment outcome profile. Addiction, 103, 1450–1460
   PubMed Web of Science ®Google Scholar
• Masher, L., Jalaudin, B., Chant, K. G., Jayasuriya, R., Sladden, T., Kaldor, J. M., & Sargent, P. L. (2006). Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction, 101, 1499–1508
   PubMedGoogle Scholar
• Nelligan, J. A., Loftis, J. M., Matthews, A. M., Zucker, B. L., Linke, A. M., & Hauser, P. (2008). Depression co-morbidity and antidepressant use in veterans with chronic hepatitis C: Results from a retrospective chart review. The Journal of Clinical Psychiatry, 69, 810–816
   PubMedGoogle Scholar
• Nobari, R. F., Meshkati, M., Ataei, B., Yazdani, M. R., Heidari, K., Kassaian, N., Nokhodian, Z., Shoaei, P., Yaran, M., & Adibi, P. (2012). Identification of Patients with Hepatitis C virus infection in persons with background of intravenous drug use: The first community announcement-based study from Iran. International Journal of Preventive Medicine, 3, 170–175
   Google Scholar
• Osher, F. C., Goldberg, R. W., McNary, S. W., Swartz, M. S., Essock, S. M., Butterfield, M. I., Rosenberg, S. D., & Five-Site Health and Risk Study Research Committee. (2003). Substance abuse and the transmission of hepatitis C among persons with severe mental illness. Psychiatric Service, 54, 842–847
   PubMed Web of Science ®Google Scholar
• Steiner, J., Lussier, R., & Rosenblatt, W. (1992). Knowledge about and risk factors for AIDS in a day hospital population. Hospital and Community Psychiatry, 43, 734–735
   PubMedGoogle Scholar
• Stewart, R., Soremekun, M., Perera, G., Broadbent, M., Callard, F., Denis, M., Hotopf, M., Thornicroft, G., & Lovestone, S. (2009). The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: Development and descriptive data. BMC Psychiatry, 9, 51
   PubMed Web of Science ®Google Scholar
• Teutsch, S., Luciani, F., Scheuer, N., McCredie, L., Hosseinv, P., Rawlinson, W., Kaldor, J., Dore, G. J., Dolan, K., Ffrench, R., Lloyd, A., Haber, P., & Levy, M. (2010). Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. BMC Public Health, 10, 633
   PubMed Web of Science ®Google Scholar
• Weaver, T., Renton, A., Stimson, G., & Tyrer, P. (1999). Severe mental illness and substance misuse-research is needed to underpin policy and services for patients with comorbidity. BMJ, 1999, 137–138
   Google Scholar
• World Health Organization. (2004). Neuroscience of psychoactive substance use and dependence (pp. 170–188). Geneva: World Health Organization
   Google Scholar
• World Health Organization. Media Center Fact Sheet 164 (2012). Available from http://www.who.int/mediacentre/factsheets/fs164/en/ [last accessed 6 Jan 2013]
   Google Scholar